favipiravir in COVID 19 all comers - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death or transfer to ICUdetailed results jRCTs041190120, 2020 (REV) 0.98 [0.02; 50.37]
0.98 [0.02 ; 50.37 ] jRCTs041190120, 2020 (REV) 1 0% 89 NA not evaluable deathsdetailed results Lou (FAVIPIRAVIR), 2020 1.12 [0.02; 62.74]
1.12 [0.02 ; 62.74 ] Lou (FAVIPIRAVIR), 2020 1 0% 19 NA not evaluable clinical improvementdetailed results Lou (FAVIPIRAVIR), 2020 1.25 [0.21; 7.62]
1.25 [0.21 ; 7.62 ] Lou (FAVIPIRAVIR), 2020 1 0% 19 NA not evaluable clinical improvement (14-day)detailed results Lou (FAVIPIRAVIR), 2020 1.25 [0.21; 7.62]
1.25 [0.21 ; 7.62 ] Lou (FAVIPIRAVIR), 2020 1 0% 19 NA not evaluable death or ventilationdetailed results NCT04310228-FAVI (Zhao), 2020 3.60 [0.13; 102.66]
3.60 [0.13 ; 102.66 ] NCT04310228-FAVI (Zhao), 2020 1 0% 12 NA not evaluable radiologic improvement (14-day)detailed results NCT04310228-FAVI (Zhao), 2020 0.32 [0.06; 1.63]
0.32 [0.06 ; 1.63 ] NCT04310228-FAVI (Zhao), 2020 1 0% NA not evaluable viral clearance detailed results jRCTs041190120, 2020 (REV) 0.71 [0.38; 1.31]
Lou (FAVIPIRAVIR), 2020 0.18 [0.01; 4.75]
0.67 [0.37 ; 1.24 ] jRCTs041190120, 2020 (REV), Lou (FAVIPIRAVIR), 2020 2 0% 108 serious not evaluable viral clearance (time to event analysis only)detailed results jRCTs041190120, 2020 (REV) 0.71 [0.38; 1.31]
0.71 [0.38 ; 1.31 ] jRCTs041190120, 2020 (REV) 1 0% 89 NA not evaluable viral clearance by day 14detailed results Lou (FAVIPIRAVIR), 2020 0.18 [0.01; 4.75]
0.18 [0.01 ; 4.75 ] Lou (FAVIPIRAVIR), 2020 1 0% 19 NA not evaluable ICU admissiondetailed results Lou (FAVIPIRAVIR), 2020 5.43 [0.21; 139.89]
5.43 [0.21 ; 139.89 ] Lou (FAVIPIRAVIR), 2020 1 0% 19 NA not evaluable adverse eventsdetailed results NCT04310228-FAVI (Zhao), 2020 0.60 [0.05; 6.80]
0.60 [0.05 ; 6.80 ] NCT04310228-FAVI (Zhao), 2020 1 0% 12 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-21 23:57 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 94
- treatments: 513
- roots T: 290